242 related articles for article (PubMed ID: 26019441)
1. Hepatitis C: New challenges in liver transplantation.
Filipec Kanizaj T; Kunac N
World J Gastroenterol; 2015 May; 21(19):5768-77. PubMed ID: 26019441
[TBL] [Abstract][Full Text] [Related]
2. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
4. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
5. Current management and perspectives for HCV recurrence after liver transplantation.
Coilly A; Roche B; Samuel D
Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.
Gitto S; Belli LS; Vukotic R; Lorenzini S; Airoldi A; Cicero AF; Vangeli M; Brodosi L; Panno AM; Di Donato R; Cescon M; Grazi GL; De Carlis L; Pinna AD; Bernardi M; Andreone P
World J Gastroenterol; 2015 Apr; 21(13):3912-20. PubMed ID: 25852276
[TBL] [Abstract][Full Text] [Related]
7. Recurrent hepatitis C after liver transplant.
deLemos AS; Schmeltzer PA; Russo MW
World J Gastroenterol; 2014 Aug; 20(31):10668-81. PubMed ID: 25152571
[TBL] [Abstract][Full Text] [Related]
8. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.
Khaderi S; Shepherd R; Goss JA; Leung DH
World J Gastroenterol; 2014 Aug; 20(32):11281-6. PubMed ID: 25170212
[TBL] [Abstract][Full Text] [Related]
10. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
Weiler N; Zeuzem S; Welker MW
World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
[TBL] [Abstract][Full Text] [Related]
12. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
13. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
15. Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Kalafateli M; Dusheiko G; Manousou P
J Gastrointestin Liver Dis; 2015 Jun; 24(2):257-8. PubMed ID: 26114189
[No Abstract] [Full Text] [Related]
16. Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
Castells L; Llaneras J; Campos-Varela I; Bilbao I; Crespo M; Len O; Rodríguez-Frías F; Charco R; Salcedo T; Esteban JI; Esteban-Mur R
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):86-93. PubMed ID: 28051797
[TBL] [Abstract][Full Text] [Related]
17. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
[TBL] [Abstract][Full Text] [Related]
18. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
Suraweera D; Saab EG; Tong MJ; Saab S
Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
[TBL] [Abstract][Full Text] [Related]
19. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
Grassi A; Ballardini G
World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and outcome of hepatitis C relapse in transplant recipients.
Angelico M
Transplant Proc; 2011; 43(6):2457-8. PubMed ID: 21839293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
